RxDoctor Payments Data

Steven Fein, MD

Gastroenterology · Pasadena, TXNPI 1003819582

Payments from drug & device makers

$9,583in general payments, 2019–2025

Across 96 payments — averaging $99.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB Biosciences Inc.$6K
  • Ferring International Pharmascience Center US$2K
  • AbbVie$701
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$315
  • American Regent$253
  • Sanofi$101
  • plus $612 from 14 others

What the payments were for

  • Food & beverage$1,83097%
  • Gifts$533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,583 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$16,051
Medicare patients
87
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine38$17,136
LinzessLinaclotide12$12,589
Sucralfate67$7,703
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,233
Pantoprazole Sodium235$3,214
Omeprazole93$1,553
Dicyclomine Hcl56$1,476
Famotidine63$1,461
Colestipol Hcl29$1,392
Esomeprazole Magnesium20$1,087
Rabeprazole Sodium13$905
Metoclopramide Hcl55$610
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$595
Ondansetron OdtOndansetron32$473
Liothyronine Sodium11$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$701$12,58912 claims
Braintree Laboratories, Inc.Sutab$53$3,23320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →